相似文献
1
Should minimal residual disease negativity be the end point of myeloma therapy?
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
2
Should minimal residual disease negativity be the end point of myeloma therapy?
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
3
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
4
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
5
ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.
Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560.
6
Related haploidentical donors are a better choice than matched unrelated donors: Point.
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
7
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
8
Platelets and hemostasis: a new perspective on an old subject.
Blood Adv. 2016 Nov 22;1(1):5-9. doi: 10.1182/bloodadvances.2016000059. eCollection 2016 Nov 29.
9
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
10
Platelets as immune-sensing cells.
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
引用本文的文献
1
Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.
Eur Radiol. 2022 Apr;32(4):2135-2148. doi: 10.1007/s00330-021-08311-z. Epub 2022 Jan 14.
2
Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.
Cancers (Basel). 2021 Sep 12;13(18):4582. doi: 10.3390/cancers13184582.
3
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.
Bone Marrow Transplant. 2020 Jun;55(6):1137-1146. doi: 10.1038/s41409-020-0791-y. Epub 2020 Jan 28.
4
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.
Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699. eCollection 2019.
5
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.
Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20.
6
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Int J Mol Sci. 2018 Jan 24;19(2):340. doi: 10.3390/ijms19020340.
7
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Drugs. 2017 Dec;77(18):2013-2024. doi: 10.1007/s40265-017-0837-7.
本文引用的文献
1
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
2
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
3
Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.
JAMA Oncol. 2017 Jan 1;3(1):18-20. doi: 10.1001/jamaoncol.2016.3112.
4
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.
5
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
6
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
7
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.
Cancer Biol Med. 2016 Jun;13(2):215-25. doi: 10.20892/j.issn.2095-3941.2016.0025.
8
A new era of immune therapy in multiple myeloma.
Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856.
9
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
10
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
J Natl Compr Canc Netw. 2016 Apr;14(4):389-400. doi: 10.6004/jnccn.2016.0046.
Zotero 插件